FDA‐approved immunotherapies are presently undergoing clinical trials for stage I lung cancer, including the programmed cell death ligand 1 (PD‐L1) inhibitor durvalumab as consolidation treatment with radiotherapy, as well as the PD‐1 inhibitor pembrolizumab.5, 6. Here, CD274 is linked to lung cancer.